文献速递脑血管病外科神经重症

脑动静脉畸形的外科治疗:一项实用性随机试验注册研究中患者的临床结局

Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial.
PubMed 文献 · J Neurosurg · 2022-09-09

TOBAS研究的外科注册部分纳入2014年6月至2021年5月30个中心的患者,其中152例进入外科注册,139例纳入分析。手术血管造影治愈率为89%(95%CI 82%-93%),低级别为95%(95%CI 90%-98%)。平均随访18.1个月,12%患者达到mRS>2的主要安全性结局,永久治疗相关并发症导致mRS>2者为4%。

要点

  • 外科注册139例中,手术血管造影全级别治愈率89%,低级别95%。
  • 平均随访18.1个月,12%患者mRS>2,永久治疗相关并发症致mRS>2者4%。
  • 需更多患者、外科医生和中心参与随机试验以明确外科治疗未破裂脑动静脉畸形的作用。

核心结论

  • TOBAS注册中脑动静脉畸形的外科治疗治愈率为88%。
  • 需要更多患者、外科医生和中心参与随机试验,以最终确定外科治疗在未破裂脑动静脉畸形治疗中的作用。

研究设计与样本

  • TOBAS是一项实用性研究,包括2项随机试验以及接受治疗或保守管理患者的注册研究。
  • 2014年6月至2021年5月,在30个TOBAS中心共招募1010例患者。
  • 考虑治愈性治疗的患者中,229/512例(44%)选择手术;其中77例(34%)纳入手术与观察随机试验,152例(66%)进入外科注册。
  • 外科注册患者中,124/152例(82%)为破裂动静脉畸形,28/152例(18%)为未破裂;118/152例(78%)为低级别Spetzler-Martin I-II级。
  • 排除13例后,139例纳入分析。

主要发现

  • 外科注册患者中,78/139例(56%)在手术前接受栓塞治疗。
  • 手术血管造影治愈率:全级别123/139例(89%,95%CI 82%-93%),低级别105/110例(95%,95%CI 90%-98%)。
  • 平均随访18.1个月,16例(12%,95%CI 7%-18%)达到主要安全性结局mRS>2,其中11/16例因既往动静脉畸形破裂而基线mRS≥3。
  • 29例(21%,95%CI 15%-28%)发生严重不良事件。
  • 永久治疗相关并发症导致mRS>2者6/139例(4%,95%CI 2%-9%),其中5例(83%)的并发症由术前栓塞导致。

关键数值与推荐

  • 主要结局为10年时mRS>2(本报告为末次随访时)。
  • 次要结局包括血管造影结果、围手术期严重不良事件以及导致mRS>2的永久治疗相关并发症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a pragmatic study that includes 2 randomized trials and registries of treated or conservatively managed patients. The authors report the results of the surgical registry. METHODS: TOBAS patients are managed according to an algorithm that combines clinical judgment and randomized allocation. For patients considered for curative treatment, clinicians selected from surgery, endovascular therapy, or radiation therapy as the primary curative method, and whether observation was a reasonable alternative. When surgery was selected and observation was deemed unreasonable, the patient was not included in the randomized controlled trial but placed in the surgical registry. The primary outcome of the trial was mRS score > 2 at 10 years (at last follow-up for the current report). Secondary outcomes include angiographic results, perioperative serious adverse events, and permanent treatment-related complications leading to mRS score > 2. RESULTS: From June 2014 to May 2021, 1010 patients were recruited at 30 TOBAS centers. Surgery was selected for 229/512 patients (44%) considered for curative treatment; 77 (34%) were included in the surgery versus observation randomized trial and 152 (66%) were placed in the surgical registry. Surgical registry patients had 124/152 (82%) ruptured and 28/152 (18%) unruptured arteriovenous malformations (AVMs), with the majority categorized as low-grade Spetzler-Martin grade I-II AVM (118/152 [78%]). Thirteen patients were excluded, leaving 139 patients for analysis. Embolization was performed prior to surgery in 78/139 (56%) patients. Surgical angiographic cure was obtained in 123/139 all-grade (89%, 95% CI 82%-93%) and 105/110 low-grade (95%, 95% CI 90%-98%) AVM patients. At the mean follow-up of 18.1 months, 16 patients (12%, 95% CI 7%-18%) had reached the primary safety outcome of mRS score > 2, including 11/16 who had a baseline mRS score ≥ 3 due to previous AVM rupture. Serious adverse events occurred in 29 patients (21%, 95% CI 15%-28%). Permanent treatment-related complications leading to mRS score > 2 occurred in 6/139 patients (4%, 95% CI 2%-9%), 5 (83%) of whom had complications due to preoperative embolization. CONCLUSIONS: The surgical treatment of brain AVMs in the TOBAS registry was curative in 88% of patients. The participation of more patients, surgeons, and centers in randomized trials is needed to definitively establish the role of surgery in the treatment of unruptured brain AVMs. Clinical trial registration no.: NCT02098252 (ClinicalTrials.gov).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Darsaut TE, Magro E, Bojanowski MW, et al. Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial. J Neurosurg. 2022. PMID: 36087316. doi:10.3171/2022.7.JNS22813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。